Anthony James Culverwell Acquires 100,000 Shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Stock

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Director Anthony James Culverwell purchased 100,000 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $0.45 per share, with a total value of $45,000.00. Following the completion of the purchase, the director now owns 100,317 shares of the company’s stock, valued at approximately $45,142.65. This represents a 31,545.74 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Quoin Pharmaceuticals Price Performance

Shares of NASDAQ:QNRX traded down $0.01 during trading on Friday, reaching $0.55. 553,804 shares of the stock were exchanged, compared to its average volume of 1,118,553. The stock has a fifty day moving average of $0.68 and a two-hundred day moving average of $0.63. Quoin Pharmaceuticals, Ltd. has a 1-year low of $0.43 and a 1-year high of $6.18. The firm has a market cap of $2.78 million, a price-to-earnings ratio of -0.14 and a beta of 1.79.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.